Ngā hua rapu - Vladimir Tolmachev

Whakamahine hua
  1. 1
    Affibody Molecules as Targeting Vectors for PET Imaging

    Affibody Molecules as Targeting Vectors for PET Imaging mā Vladimir Tolmachev, Anna Orlova

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Methods for Radiolabelling of Monoclonal Antibodies

    Methods for Radiolabelling of Monoclonal Antibodies mā Vladimir Tolmachev, Anna Orlova, Karl Andersson

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a <sup>124</sup>I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model

    On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a <sup>124</sup>I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model mā Anna Orlova, Helena Wållberg, Sharon Stone‐Elander, Vladimir Tolmachev

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond

    Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond mā Javad Garousi, Anna Orlova, Fredrik Y. Frejd, Vladimir Tolmachev

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications

    Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications mā John Löfblom, Joachim Feldwisch, Vladimir Tolmachev, J. Carlsson, S. Ståhl, Fredrik Y. Frejd

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Tumor Targeting Using Affibody Molecules: Interplay of Affinity, Target Expression Level, and Binding Site Composition

    Tumor Targeting Using Affibody Molecules: Interplay of Affinity, Target Expression Level, and Binding Site Composition mā Vladimir Tolmachev, Thuy Tran, Daniel Rosik, Anna Sjöberg, Lars Abrahmsén, Anna Orlova

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain

    Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain mā Jan Terje Andersen, Rikard Pehrson, Vladimir Tolmachev, Muluneh Bekele Daba, Lars Abrahmsén, Caroline Ekblad

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Affibody-mediated PET imaging of HER3 expression in malignant tumours

    Affibody-mediated PET imaging of HER3 expression in malignant tumours mā Maria� Rosestedt, Karl Andersson, Bogdan Mitran, Vladimir Tolmachev, John Löfblom, Anna Orlova, Stefan Ståhl

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Selection and characterization of HER2/neu-binding affibody ligands

    Selection and characterization of HER2/neu-binding affibody ligands mā Maria Wikman, A.-C. Steffen, Elin Gunneriusson, Vladimir Tolmachev, Gregory P. Adams, J. Carlsson, S. Ståhl

    I whakaputaina 2004
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors

    Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors mā Hadis Honarvar, Kristina Westerlund, Mohamed Altai, Mattias Sandström, Anna Orlova, Vladimir Tolmachev, Amelie Eriksson Karlström

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Influence of Nuclides and Chelators on Imaging Using Affibody Molecules: Comparative Evaluation of Recombinant Affibody Molecules Site-Specifically Labeled with <sup>68</sup>Ga and <sup>111</sup>In via Maleimido Derivatives of DOTA and NODAGA

    Influence of Nuclides and Chelators on Imaging Using Affibody Molecules: Comparative Evaluation of Recombinant Affibody Molecules Site-Specifically Labeled with <sup>68</sup>Ga and... mā Mohamed Altai, Joanna Strand, Daniel Rosik, Ram Kumar Selvaraju, Amelie Eriksson Karlström, Anna Orlova, Vladimir Tolmachev

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Influence of Macrocyclic Chelators on the Targeting Properties of 68Ga-Labeled Synthetic Affibody Molecules: Comparison with 111In-Labeled Counterparts

    Influence of Macrocyclic Chelators on the Targeting Properties of 68Ga-Labeled Synthetic Affibody Molecules: Comparison with 111In-Labeled Counterparts mā Joanna Strand, Hadis Honarvar, Anna Perols, Anna Orlova, Ram Kumar Selvaraju, Amelie Eriksson Karlström, Vladimir Tolmachev

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Molecular Design and Optimization of <sup>99m</sup>Tc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties

    Molecular Design and Optimization of <sup>99m</sup>Tc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties mā Helena Wållberg, Anna Orlova, Mohammed Altai, Seyed Jalal Hosseinimehr, Charles Widström, Jennie Malmberg, Stefan Ståhl, Vladimir Tolmachev

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Molecular Imaging of <i>HER2</i>-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic <sup>111</sup>In- or <sup>68</sup>Ga-Labeled Affibody Molecules

    Molecular Imaging of <i>HER2</i>-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic <sup>111</sup>In- or <sup>68</sup>Ga-Labeled Affibody Molecules mā Richard P. Baum, Vikas Prasad, Dirk Müller, Christiane Schuchardt, Anna Orlova, Anders Wennborg, Vladimir Tolmachev, Joachim Feldwisch

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer

    Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer mā Linda C. Sandin, Anna Orlova, Erika Gustafsson, Peter Ellmark, Vladimir Tolmachev, Thomas H. Tötterman, Sara M. Mangsbo

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules

    PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules mā Javad Garousi, Karl Andersson, Bogdan Mitran, MARIE-LOUISE PICHL, Stefan Ståhl, Anna Orlova, John Löfblom, Vladimir Tolmachev

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule<sup>111</sup>In-DOTA-Z<sub>IGF1R:4551</sub>

    Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule<sup>111</sup>In-DOTA-Z<sub>IGF1R:4551</sub> mā Vladimir Tolmachev, Jennie Malmberg, Camilla Hofström, Lars Abrahmsén, Thomas Bergman, Anna Sjöberg, Mattias Sandström, Torbjörn Gräslund, Anna Orlova

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT

    Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT mā Dan Sandberg, Vladimir Tolmachev, Irina Velikyan, Helena Olofsson, Anders Wennborg, Joachim Feldwisch, Jörgen Carlsson, Henrik Lindman, Jens Sörensen

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    HAHAHA, HEHEHE, HIHIHI, or HKHKHK: Influence of Position and Composition of Histidine Containing Tags on Biodistribution of [<sup>99m</sup>Tc(CO)<sub>3</sub>]<sup>+</sup>-Labeled Affibody Molecules

    HAHAHA, HEHEHE, HIHIHI, or HKHKHK: Influence of Position and Composition of Histidine Containing Tags on Biodistribution of [<sup>99m</sup>Tc(CO)<sub>3</sub>]<sup>+</sup>-Labeled A... mā Camilla Hofström, Mohamed Altai, Hadis Honarvar, Joanna Strand, Jennie Malmberg, Seyed Jalal Hosseinimehr, Anna Orlova, Torbjörn Gräslund, Vladimir Tolmachev

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Pharmacokinetics and red cell utilization of iron(III) hydroxide–sucrose complex in anaemic patients: a study using positron emission tomography

    Pharmacokinetics and red cell utilization of iron(III) hydroxide–sucrose complex in anaemic patients: a study using positron emission tomography mā Soheir Beshara, Hans Lundqvist, Johanna Sundin, Mark Lubberink, Vladimir Tolmachev, Sven Valind, Gunnar Antoni, Bengt Långström, Bo G. Danielson

    I whakaputaina 1999
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: